Sanofi boosts its mRNA capabilities with Translate Bio acquisition
Sanofi will acquire Translate Bio for approximately $3.2bn, or $38.00 per share in cash
Read More
Tag: mRNA technology
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
